Molecule.one leverages artificial intelligence (AI) to design novel chemical syntheses. As a response to the outbreak of the Covid-19 pandemic, the Polish start-up based in Warsaw has set out on the mission to accelerate the process of creating medicines.
Iris.ai was founded at Singularity University at NASA Ames Research Park in 2015. Challenged to come up with an idea that would positively impact the lives of 1 billion people, the team was formed and problem areas were explored.
New therapies to address unmet and emerging medical needs are being discovered at an explosive rate, building on rapid advances in molecular biology and genetics.
Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs.
Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs. Indeed, medicinal chemists face a challenge of their own. Trying to survive in a changing environment where pharma is focusing on biologics drug candidates will require chemists to adapt.
